Astrazeneca and Mitsubishi have signed a pharma alliance for early-stage three-year research collaboration to develop small molecule candidates from their respective portfolios that have been identified as treatments for the disease which involves kidney failure due to diabetes.
Diabetic nephropathy occurs in as many as 50% of patients who have diabetes for 20 years or more.
The research will be performed at MTPC’s facilities in Japan and at AstraZeneca’s cardiovascular and metabolic disease innovative medicines unit in Molndal, Sweden.
There is no financial commitment for the research involved and each firm will contribute equal resources at their own cost.
For further deal information visit Current Agreements (subscription required)
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity